Everest Group Names Medidata a "Leader" and "Star Performer" in Decentralized Clinical Trial Platforms

Medidata recognized for continued growth in market impact and vision in 2023 ‘Everest Group PEAK Matrix Assessment’

• Medidata Sensor Cloud noted as a strength for unifying data on a single data platform
• Circuit Clinical partnership important to enhancing expertise across therapy areas
• Project management capabilities cited by clients as a key differentiator
• Governance, security, and compliance are among Medidata’s highly rated offering

New York – December, 13 2022 – Medidata, a Dassault Systèmes company, has been  named a Leader and Star Performer in the “Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023” by Everest Group. The annual report evaluates decentralized clinical trial (DCT) products from 24 companies based on vision, capability, and market impact.

“Medidata provides a modular DCT platform with a unified data layer. Its solution is highly recognized for governance, security, and compliance by clients,” said Chunky Satija, vice president at Everest Group. “Medidata’s investments towards standardizing the site operations, improving the ease of use of the platform, expanding access to clinical trials, and unifying reporting from a single data platform have put Medidata into a leader’s position in the decentralized clinical trial platforms PEAK Matrix Assessment.” 

Leaders in the DCT Platforms PEAK Matrix Assessment:

• Offer clients an end-to-end modular platform with a unified data model that allows all patient data to be in a single repository, eliminating data silos
• Provide the auxiliary services required to run a DCT
• Are ranked high on user and patient experience, and they offer advanced use cases to clients (such as advanced analytics and patient recruitment campaigns) to enable them to run their DCTs
• Work proactively toward building market awareness and stakeholder education via various forums and enjoy high mindshare and brand perception

“As the industry has evolved and demand for DCTs has grown, Medidata has been at the forefront of driving innovation for patient-centric technologies.” said Anthony Costello, CEO of Medidata Patient Cloud. “Recognition from Everest as both a Leader and Star Performer validates the success we have gained with our sponsors and CROs. Our depth and breadth of solutions across therapy areas, and our project management capabilities were key to earning our spot as a Leader,” 

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.